|
Treatment of angiosarcoma with pazopanib and paclitaxel: Results of the phase II trial of the German Interdisciplinary Sarcoma Group (GISG-06 EVA) study. |
|
|
Honoraria - Lilly; Novartis; PharmaMar |
Research Funding - Lilly; PharmaMar |
Travel, Accommodations, Expenses - Lilly; Novartis; PharmaMar |
|
|
Honoraria - Bayer; GlaxoSmithKline; Novartis; Pfizer; Pharmamar |
Consulting or Advisory Role - Bayer; Blueprint Medicines; Deciphera; Lilly; Nanobiotix |
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis |
Travel, Accommodations, Expenses - Pharmamar |
|
|
Honoraria - Amgen; Bayer; Eisai; Lilly; Novartis; PharmaMar; Roche |
Consulting or Advisory Role - Amgen; Bayer; Eisai; Lilly; Novartis; PharmaMar |
Travel, Accommodations, Expenses - PharmaMar |
|
|
Honoraria - Bayer; Lilly; Novartis; Pfizer; PharmaMar |
Consulting or Advisory Role - ARIAD; Clinigen Group; Lilly; Merck; Novartis; Pfizer; PharmaMar; Roche |
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Eisai; Lilly; Novartis; Pfizer |
Consulting or Advisory Role - Arog; Eisai; Lilly; Nanobiotix; Novartis; PharmaMar |
Travel, Accommodations, Expenses - PharmaMar |